Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05992896 · ClinicalTrials.gov registry record · Phase 4
A Study of Loco-Regional Liposomal Bupivacaine Injection
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT05992896: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT05992896 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05992896, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research is to find out if using liposomal bupivacaine solution (bupivacaine liposome) injections during lower extremity revascularization surgery will lower the amount of narcotic drugs used during and following the procedure.
Primary Outcome
The amount of narcotics used postoperatively 12 hours after injection, measured in morphine equivalent.
Interventions
- DRUG Placebo
- DRUG Bupivacaine liposome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 4 |
Why NCT05992896 stopped before completion
NCT05992896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05992896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05992896 about?
NCT05992896 is a clinical study titled "A Study of Loco-Regional Liposomal Bupivacaine Injection". The purpose of this research is to find out if using liposomal bupivacaine solution (bupivacaine liposome) injections during lower extremity revascularization surgery will lower the amount of narcotic drugs used during and following the procedure.
What is the current status of trial NCT05992896?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2023-09-26. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05992896?
The interventions under investigation include: Placebo (DRUG), Bupivacaine liposome (DRUG).
Who is sponsoring clinical trial NCT05992896?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05992896's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI